Clinical Trial Update: Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating Olvi-Vec in combination with platinum-doublet chemotherapy and Bevacizumab versus physician's choice of chemotherapy plus Beva…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrioid Ovarian Cancer
• Fallopian Tube Cancer
• High-grade Serous Ovarian Cancer
• Ovarian Clear Cell Carcinoma
• Peritoneal Cancer
• Platinum-refractory Ovarian Cancer
• Platinum-resistant Ovarian Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Olvi-Vec

Snippet

Sponsor: Genelux Corporation | Conditions: Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer | Phase 3 | Status: RECRUITING